Innovation in Enzyme Replacement Therapy Devices Reduce Chronic Diseases and Improve Patient’s Quality Life. Know More Opportunities with FMI

The Gaucher and Pompe diseases enzyme replacement therapy (ERT) market is anticipated to capture a valuation of US$ 3.3 billion in 2023 and is projected to rise to US$ 6.2 billion by 2033. The market is likely to secure a CAGR of 6.6% during the forecast period.

The rising enzyme deficiencies and lysosomal storage disorders like Gaucher, Pompe, and Fabry drive market growth. Rising patient awareness to increase the adoption of Pompe disease treatment is propelling the market size. In addition, growing metabolic diseases, harmful body cells, and rare diseases are increasing the demand for Gaucher and Pompe diseases enzyme replacement therapy (ERT).

Get Latest Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-12771

Healthcare manufacturers are indulged in developing advanced enzyme replacement therapy treatments that influence market opportunities. Several life-threatening chronic diseases are increasing the demand for Gaucher disease diagnosis by healthcare providers. In addition, growing economies, the medical tourism industry, and huge investments are bolstering market opportunities.

According to a report published by National Fabry Foundation, in May 2020, around 7,713 people suffered from Fabry disease in the United States. Similarly, in August 2021, according to a report by the National Institute of Neurological Disorders and Stroke, nearly 40,000 people suffered from Pompe disease in the United States.

High Treatment Costs Hamper the Market Growth

The availability of treatment resources for rare disorders is fueling market growth. Conversely, the increasing treatment and therapy costs and lack of skilled professionals limit the market growth. Moreover, the availability of alternative or low-cost solutions and therapies is restraining the market growth.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-12771

Key Takeaways:

• The Gaucher and Pompe diseases enzyme replacement therapy (ERT) market is expected to have a valuation of US$ 6.2 billion by 2033.
• With a CAGR of 6.6%, the global market is increasing during the forecast period.
• The market in the United States is anticipated to capture 6.1% of the CAGR through 2033.
• The United Kingdom Gaucher and Pompe diseases enzyme replacement therapy (ERT) market is expected to thrive at a CAGR of 6.9% during the forecast period.
• China market is expected to secure a CAGR of 7.1% over the forecast period.
• Canada market may capture a CAGR of 6.9% by 2033.

Who is Winning?

Key players focus on patients’ requirements and launching innovative products to improve their health. Research and development in advanced therapy treatment equipment for patients for a better quality of life with compelling results may drive market growth.

Players upsurge the market size through marketing methodologies, including agreements, collaborations, partnerships, product launches, mergers, and acquisitions.

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-12771

Other Prominent Players in the Global Market:

• Alexion Pharmaceuticals, Inc.
• Pfizer
• BioMarin Pharmaceuticals Inc
• Ultragenyx Pharmaceutical Inc.
• Janssen Pharmaceuticals, Inc (J&J)
• Sigma-Tau Pharmaceuticals Inc,
• AbbVie Inc.
• Sanofi S.A.
• Shire Plc
• Merck KGaA
• Takeda Pharmaceuticals

Recent Developments in the Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market are:

• In November 2019, according to National Center for Biotechnology Information, Brineura launched enzyme replacement therapy for Neuronal Ceroid Lipofuscinosis Type 2 Disorder.

• In September 2021, Takeda Pharmaceutical Company partnered with JCR Pharmaceuticals Company for hunter syndrome treatment in the United States.

Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market by Category

By Therapeutic Condition

• Gaucher Disease:
  • Type 1 (Non-neuropathic)
  • Type 2 (Acute Infantile Neuronopathic)
  • Type 3 Gaucher Disease (Chronic Neuronopathic)
  • Perinatal Lethal Gaucher Disease
• Cardiovascular Gaucher Disease:
  • Pompe Disease
  • Classic Infantile-onset
  • Late-onset

By Route of Administration:

• Oral
• Parental

By Distribution Channel:

• Hospital Pharmacies
• Specialty Treatment Pharmacies
• Retail Pharmacies
• Online Pharmacies

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs